Skip to main content


Media Contacts:


Polina Miklush
Mobile: +1 908 608 7170

Seqirus news releases

Seqirus news releases

Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020
02 Dec 2020

Absolute Efficacy of Cell-Based Influenza Vaccines in Children Aged 2 to 18 Years, Impact of COVID-19 on Canadians’ Views of Influenza, Among Data Being Presented

COVID-19 Update
02 Apr 2020

Safeguarding our people and communities remains our top priority.

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
11 Dec 2019

/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains1.